AZN discloses issued share capital and voting rights as of Sept 30, 2025

Rhea-AI Filing Summary

AstraZeneca reported the total number of voting rights in the company as of 30 September 2025. The company states its issued share capital comprises 1,550,701,945 ordinary shares of US$0.25 and that no shares are held in treasury, giving a total of 1,550,701,945 voting rights. The notice explains this figure can be used by shareholders as the denominator to determine whether they must notify changes in their holdings under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

The disclosure is a routine Transparency Directive update and does not include financial results, transactions, or forward guidance. Contact details for Investor Relations and Media are provided and the report is signed by the Company Secretary, Matthew Bowden, dated 01 October 2025.

Insights

Corporate Governance Expert

TL;DR: Routine transparency filing confirming share count and absence of treasury shares; useful for shareholder notification calculations.

The filing provides a standard update of issued share capital and total voting rights, which is primarily administrative but necessary for compliance with UK disclosure rules. It enables shareholders and market participants to calculate ownership thresholds for mandatory notifications. There are no operational, financial, or strategic details in this document and no indications of share issuance, buybacks, or changes to capital structure beyond the stated counts.

Securities Compliance Analyst

TL;DR: Non-material compliance disclosure with clear voting-rights denominator for FCA rules; no market-moving information.

This Form 6-K furnishes the total voting rights number required under the Transparency Directive. The explicit statement that no shares are held in treasury clarifies the full count of exercisable votes. From a regulatory perspective, the filing meets routine disclosure obligations and assists investors in meeting their notification duties. It contains no signals of corporate action or changes to capital beyond the static share count.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of October 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights

1 October 2025

Transparency Directive

Voting rights and capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 September 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,701,945 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,701,945.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date:01 October 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What is the total number of voting rights for AstraZeneca (AZN)?

The total number of voting rights is 1,550,701,945 ordinary shares.

As of what date does the reported voting rights figure apply for AZN?

The figure applies as at 30 September 2025 and is disclosed in the Form 6-K dated 01 October 2025.

Does AstraZeneca hold any treasury shares that reduce the voting rights denominator?

No. The filing states no shares are held in Treasury, so the issued share capital equals the total voting rights.

How should shareholders use the total voting rights number?

Shareholders may use the 1,550,701,945 figure as the denominator to determine whether they must notify changes in their interest under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Who signed the Form 6-K for AstraZeneca?

The report is signed by Matthew Bowden, Company Secretary of AstraZeneca PLC.